These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35421019)

  • 1. Efficacy of omega-3-rich Camelina sativa on the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, controlled trial.
    Musazadeh V; Dehghan P; Khoshbaten M
    Eur J Gastroenterol Hepatol; 2022 May; 34(5):537-545. PubMed ID: 35421019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of hydroxy citric acid supplementation with calorie-restricted diet on metabolic, atherogenic and inflammatory biomarkers in women with non-alcoholic fatty liver disease: a randomized controlled clinical trial.
    Arefhosseini S; Tutunchi H; Nomi-Golzar S; Mahboob S; Pouretedal Z; Ebrahimi-Mameghani M
    Food Funct; 2022 May; 13(9):5124-5134. PubMed ID: 35416190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omega 3-rich Camelina sativa oil in the context of a weight loss program improves glucose homeostasis, inflammation and oxidative stress in patients with NAFLD: A randomised placebo-controlled clinical trial.
    Musazadeh V; Dehghan P; Saleh-Ghadimi S; Abbasalizad Farhangi M
    Int J Clin Pract; 2021 Nov; 75(11):e14744. PubMed ID: 34423525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
    Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sour tea supplementation on liver enzymes, lipid profile, blood pressure, and antioxidant status in patients with non-alcoholic fatty liver disease: A double-blind randomized controlled clinical trial.
    Izadi F; Farrokhzad A; Tamizifar B; Tarrahi MJ; Entezari MH
    Phytother Res; 2021 Jan; 35(1):477-485. PubMed ID: 32909326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of sesame oil consumption compared to sunflower oil on lipid profile, blood pressure, and anthropometric indices in women with non-alcoholic fatty liver disease: a randomized double-blind controlled trial.
    Vahedi H; Atefi M; Entezari MH; Hassanzadeh A
    Trials; 2022 Jul; 23(1):551. PubMed ID: 35804451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes.
    Tutunchi H; Ostadrahimi A; Saghafi-Asl M; Hosseinzadeh-Attar MJ; Shakeri A; Asghari-Jafarabadi M; Roshanravan N; Farrin N; Naemi M; Hasankhani M
    Pharmacol Res; 2020 Jun; 156():104770. PubMed ID: 32217148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial.
    Asghari S; Asghari-Jafarabadi M; Somi MH; Ghavami SM; Rafraf M
    J Am Coll Nutr; 2018; 37(3):223-233. PubMed ID: 29313746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
    Janczyk W; Lebensztejn D; Wierzbicka-Rucińska A; Mazur A; Neuhoff-Murawska J; Matusik P; Socha P
    J Pediatr; 2015 Jun; 166(6):1358-63.e1-3. PubMed ID: 25771388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease.
    Farzin L; Asghari S; Rafraf M; Asghari-Jafarabadi M; Shirmohammadi M
    Int J Vitam Nutr Res; 2020 Jun; 90(3-4):279-289. PubMed ID: 30789808
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of green coffee extract supplementation on serum adiponectin concentration and lipid profile in patients with non-alcoholic fatty liver disease: A randomized, controlled trial.
    Hosseinabadi S; Rafraf M; Asghari S; Asghari-Jafarabadi M; Vojouhi S
    Complement Ther Med; 2020 Mar; 49():102290. PubMed ID: 32147076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
    PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of intakes of fish and Camelina sativa oil on atherogenic and anti-atherogenic functions of LDL and HDL particles: A randomized controlled trial.
    Manninen S; Lankinen M; Erkkilä A; Nguyen SD; Ruuth M; de Mello V; Öörni K; Schwab U
    Atherosclerosis; 2019 Feb; 281():56-61. PubMed ID: 30658192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of co supplementation of omega-3 and vitamin D on cardio metabolic risk factors and psychological distress in reproductive-aged women with prediabetes and hypovitaminosis D: a study protocol for a randomized controlled trial.
    Rajabi-Naeeni M; Dolatian M; Qorbani M; Vaezi AA
    Trials; 2019 Dec; 20(1):799. PubMed ID: 31888762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
    Namkhah Z; Naeini F; Mahdi Rezayat S; Mehdi Yaseri ; Mansouri S; Javad Hosseinzadeh-Attar M
    Int J Clin Pract; 2021 Nov; 75(11):e14852. PubMed ID: 34516703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial.
    Kooshki F; Moradi F; Karimi A; Niazkar HR; Khoshbaten M; Maleki V; Pourghassem Gargari B
    Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1298-1306. PubMed ID: 32804855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
    Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of saffron supplementation on some inflammatory and oxidative markers, leptin, adiponectin, and body composition in patients with nonalcoholic fatty liver disease: A double-blind randomized clinical trial.
    Pour FK; Aryaeian N; Mokhtare M; Mirnasrollahi Parsa RS; Jannani L; Agah S; Fallah S; Moradi N
    Phytother Res; 2020 Dec; 34(12):3367-3378. PubMed ID: 32798261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease].
    Wang W; Shi LP; Shi L; Xu L
    Zhonghua Nei Ke Za Zhi; 2018 Feb; 57(2):101-106. PubMed ID: 29397594
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial.
    Behrouz V; Aryaeian N; Zahedi MJ; Jazayeri S
    J Food Sci; 2020 Oct; 85(10):3611-3617. PubMed ID: 32885440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.